Get updates from ProMIS Neurosciences, Inc. (PMN) Press Releases via email, on your phone or read them on follow.it on your own custom news page.
You can filter the news from ProMIS Neurosciences, Inc. (PMN) Press Releases that get delivered to you using tags or topics or you can opt for all of them. Unsubscription is also very simple.
See the latest news from ProMIS Neurosciences, Inc. (PMN) Press Releases below.
Site title: ProMIS Neurosciences, Inc. (PMN)
Is this your feed? Claim it!
Cambridge, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that its board of directors has determined to effect a one-for-twenty-five reverse stock split of the Compa...
Phase 1b trial in Alzheimer’s disease is over 85% enrolled: Cohorts 1 and 2 are fully enrolled
PMN310 continues to demonstrate a favorable safety profile
On track to report 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026
Cambridge, Massachusetts, Nov. 12...
Cambridge, Massachusetts, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, and members of senior management will...
Appointment reinforces ProMIS Neurosciences’ strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer’s program, PMN310
Cambridge, Massachusetts, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation ...
Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level);
No cases of amyloid-related imaging abnormalities (ARIA) observed to date;
The trial, expected to enroll 128 patients, remains on track to report 6-month interim data in Q2 2026 and final 12-month top-line res...
